Small bowel lesions in patients with iron deficiency anaemia without overt bleeding: a multicentre study Angelo ZulloVincenzo De FrancescoRoberta Elisa Rossi Original Article 09 November 2023 Pages: 1 - 4
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Hubert SchrezenmeierAustin KulasekararajJong Wook Lee Original Article Open access 07 October 2023 Pages: 5 - 15
Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children Chenzi ZhaoQing ZhangZhigang Li Original Article 18 October 2023 Pages: 17 - 28
Screening results and mutation frequency analysis of G6PD deficiency in 1,291,274 newborns in Huizhou, China: a twenty-year experience Zhiqiang ZhangXiaoting WangJianhui Jiang Original Article 16 November 2023 Pages: 29 - 36
Investigating the correlation between small molecular inhibitor utilization, peripheral blood monocytes, and treatment outcomes in Rosai Dorfman disease Samuel B. ReynoldsSabrina WilcoxAsra Z. Ahmed Original Article 09 November 2023 Pages: 37 - 59
Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study Ruiqi WangYuanyuan XuLi Yu Original Article 06 November 2023 Pages: 61 - 71
CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy Maryam Ahmed S. Al BarashdiAhlam AliKen Mills Original Article Open access 02 November 2023 Pages: 73 - 88
Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family Hiroyuki KimuraMasahiro OnozawaTakanori Teshima Original Article 14 November 2023 Pages: 89 - 96
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis Kotaro ShideKatsuto TakenakaKazuya Shimoda Original Article 10 November 2023 Pages: 97 - 103
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents Jan Philipp BewersdorfRory M. ShallisAmer M. Zeidan Original Article 01 December 2023 Pages: 105 - 116
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities Nathan P. HorvatEnas F. AbdallahAndrew T. Kuykendall Original Article 30 November 2023 Pages: 117 - 123
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group Gregorio BarilàFrancesca Maria QuagliaRenato Zambello Original Article Open access 20 September 2023 Pages: 125 - 132
T-large granular lymphocyte frequencies and correlates in disease states detected by multiparameter flow cytometry in pediatric and young adult population Manisha GadgeelIshaq Al KoohejiSüreyya Savaşan Original Article 21 September 2023 Pages: 133 - 140
Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone Duobing ZouMei LvQitian Mu Original Article 26 September 2023 Pages: 141 - 151
Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China Meiyu GuoLin NongYujun Dong Original Article 26 September 2023 Pages: 153 - 162
Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study Yu-Ce WeiWei-Xin LiuMei Dong Original Article 10 October 2023 Pages: 163 - 174
Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma Fernanda Maria SantosJose Flavio Gomes MarinVanderson Rocha Original Article 05 October 2023 Pages: 175 - 183
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma Reid W. MerrymanRobert A. ReddCaron A. Jacobson Original Article 18 October 2023 Pages: 185 - 198
Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma Aidan L. ForbergJordan UnrauKeenan T. Hartert Original Article 04 October 2023 Pages: 199 - 209
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study Qiaofeng ZhongHaizhu ChenYuankai Shi Original Article 20 October 2023 Pages: 211 - 226
Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency Signe Micas PedersenClaus Larsen FeltoftNiels Jørgensen Original Article Open access 23 October 2023 Pages: 227 - 239
CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia Xinhong FeiWeijie ZhangJingbo Wang Original Article 17 October 2023 Pages: 241 - 249
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma James A. DavisAswani ThurlapatiHamza Hashmi Original Article 18 October 2023 Pages: 251 - 258
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy Michael WinkelmannViktoria BlumenbergWolfgang G. Kunz Original Article 20 October 2023 Pages: 259 - 268
Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care Başak Bostankolu DeğirmenciZeynep Arzu YeginMünci Yağcı Original Article 25 October 2023 Pages: 269 - 283
Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection Katsuto TakenakaShigeo FujiHideki Nakasone Original Article 10 November 2023 Pages: 285 - 296
Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia Jieyu TianAng WeiMaoquan Qin Original Article 22 November 2023 Pages: 297 - 305
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT Noriharu NakagawaKen IshiyamaYasushi Miyazaki Original Article 08 November 2023 Pages: 307 - 320
Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience Albert EsquirolIrene Garcia CadenasRodrigo Martino Original Article 16 November 2023 Pages: 321 - 334
Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report Qingqing LinPeipei YeYing Lu Letter to the Editor 20 September 2023 Pages: 335 - 337
Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review Wenqiang YanRui LvGang An Letter to the Editor 25 September 2023 Pages: 339 - 341
Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report Xianbo HuangShasha WangJiejing Qian Letter to the Editor 22 September 2023 Pages: 343 - 345
Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma Tribikram PandaSujay RainchwarNarendra Agrawal Letter to the Editor 23 September 2023 Pages: 347 - 349
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases Nicola SgherzaPaola CurciPellegrino Musto Letter to the Editor 02 October 2023 Pages: 351 - 355
Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report Yunfei LvXingYun YaoWenjuan Yu Letter to the Editor 30 September 2023 Pages: 357 - 360
Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia Yajuan CuiHongling Peng Letter to the Editor 21 October 2023 Pages: 361 - 362
Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis Sven EisenachJan ZinkeKarin G. Schrenk Letter to the Editor Open access 16 October 2023 Pages: 363 - 365
Unicentric Castleman’s disease presenting as amyloid A cardiac amyloidosis: a case report Miao-yan ZhangJian LiLu Zhang Letter to the Editor 26 October 2023 Pages: 367 - 368
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study Juliette PénichouxHélène LanicFabrice Jardin Correction Open access 26 October 2023 Pages: 369 - 369
Correction to: A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia Rodrick BabakhanlouMarc-Elie NaderYesid Alvarado Correction 03 November 2023 Pages: 371 - 371